---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002889"
form_type: "8-K"
ticker: "SVRA"
cik: "0001160308"
company_name: "Savara Inc"
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T02:56:18.210003+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "low"
source: SEC EDGAR
---

# Savara updates corporate presentation with no new material information

## Summary
- Corporate presentation furnished as Exhibit 99.1, available on Savara's website.
- Presentation focuses on rare respiratory disease pipeline; no specific financial or clinical updates provided.
- No guidance, trial results, or material events disclosed in the filing.
- Presentation is a routine review of company strategy and pipeline.

## SEC filing metadata
- accession: 0001193125-24-002889
- form_type: 8-K
- ticker: SVRA
- cik: 0001160308
- company_name: Savara Inc
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1160308/000119312524002889/0001193125-24-002889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1160308/000119312524002889/d704842d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002889
- JSON: https://secwatch.observer/filing/0001193125-24-002889.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002889.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.